Bristol Myers Squibb Company $BMY Position Boosted by Los Angeles Capital Management LLC

Key Points

• Los Angeles Capital Management increased its Bristol Myers Squibb stake by 34.1% in the fourth quarter, buying more than 1.09 million shares and bringing its holdings to 4.32 million shares valued at about $232.8 million.
• Bristol Myers Squibb continues to attract major institutional interest, with several funds adding positions and institutions owning about 76.4% of the stock overall.
• The company’s recent news flow was generally positive, highlighted by EU approval of Opdivo plus AVD for frontline Hodgkin lymphoma and encouraging cancer data presented at ASCO 2026, supporting its oncology pipeline.

Los Angeles Capital Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 34.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,315,403 shares of the biopharmaceutical company's stock after buying an additional 1,097,684 shares during the quarter. Bristol Myers Squibb comprises 0.8% of Los Angeles Capital Management LLC's portfolio, making the stock its 20th largest holding. Los Angeles Capital Management LLC owned about 0.21% of Bristol Myers Squibb worth $232,773,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Norges Bank bought a new position in Bristol Myers Squibb in the 4th quarter worth approximately $1,947,272,000. Bank of New York Mellon Corp boosted its stake in Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC boosted its stake in Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Man Group plc boosted its stake in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock valued at $345,594,000 after purchasing an additional 5,503,391 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in Bristol Myers Squibb by 530.6% during the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company's stock valued at $245,946,000 after purchasing an additional 4,588,601 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume NYSE: BMY

Analyst Ratings Changes

A number of equities analysts have issued reports on BMY shares. Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an "overweight" rating and a $75.00 price target for the company. Cantor Fitzgerald increased their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a "neutral" rating in a research note on Wednesday, April 8th. Bank of America decreased their price target on Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research note on Thursday, April 9th. Piper Sandler reaffirmed an "overweight" rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Finally, Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and a consensus target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $57.24 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The stock has a fifty day moving average of $58.10 and a 200-day moving average of $56.52. The company has a market capitalization of $116.88 billion, a PE ratio of 16.08, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.